Related Experiment Video
Updated: Apr 20, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C
1Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA.
Abstract:
The treatment of hepatitis C virus (HCV) has made significant advances with the development of new direct-acting antivirals. Nucleotide polymerase inhibitors are one class of these new medications that have been shown to be highly effective, safe and well tolerated as part of an antiviral regimen. Sofosbuvir has become the first drug in this class to be approved for clinical use, supported by results from extensive phase II and phase III clinical trials. This review will further discuss nucleotide polymerase inhibitors, including the data supporting their use as part of interferon-free HCV treatment regimens.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Retrovirus Life Cycles
Viral Hepatitis I: Introduction
Subviral Agents
Viruses with RNA Genomes

